1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Enterococcus Infections - Pipeline Review, H2 2013

Enterococcus Infections - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 43 pages

Enterococcus Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Enterococcus Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Infections. Enterococcus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Enterococcus Infections.
- A review of the Enterococcus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Enterococcus Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Enterococcus Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Enterococcus Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Enterococcus Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Enterococcus Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Enterococcus Infections 7
Enterococcus Infections Therapeutics under Development by Companies 9
Enterococcus Infections Therapeutics under Investigation by Universities/Institutes 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Enterococcus Infections Therapeutics - Products under Development by Companies 13
Enterococcus Infections Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Enterococcus Infections Therapeutics Development 15
Rib-X Pharmaceuticals, Inc. 15
Evolva SA 16
Priaxon AG 17
Ancora Pharmaceuticals Inc. 18
Lytix Biopharma AS 19
TAXIS Pharmaceuticals, Inc. 20
Enterococcus Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
RX-04 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Hybrid Antibiotics - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
SLP-0907 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
SLP-0901 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
EV-035 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Vaccine For Enterococcus - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Berberine Derivatives - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Tetramic Acid Analogs - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Antibiotic Compounds - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Compound-A - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Compound-B - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Enterococcus Infections Therapeutics - Drug Profile Updates 38
Enterococcus Infections Therapeutics - Dormant Products 40
Enterococcus Infections - Product Development Milestones 41
Featured News and Press Releases 41
Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43



List of Tables

Number of Products Under Development for Enterococcus Infections, H2 2013 7
Products under Development for Enterococcus Infections - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Rib-X Pharmaceuticals, Inc., H2 2013 15
Evolva SA, H2 2013 16
Priaxon AG, H2 2013 17
Ancora Pharmaceuticals Inc., H2 2013 18
Lytix Biopharma AS, H2 2013 19
TAXIS Pharmaceuticals, Inc., H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 25
Enterococcus Infections Therapeutics - Drug Profile Updates 38
Enterococcus Infections Therapeutics - Dormant Products 40



List of Figures

Number of Products under Development for Enterococcus Infections, H2 2013 7
Products under Development for Enterococcus Infections - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 11
Discovery and Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 21
Assessment by Route of Administration, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Molecule Type, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 25



Companies Mentioned

Rib-X Pharmaceuticals, Inc.
Evolva SA
Priaxon AG
Ancora Pharmaceuticals Inc.
Lytix Biopharma AS
TAXIS Pharmaceuticals, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...

Rabies - Pipeline Review, H2 2016

October 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.